ChemoCentryx (CCXI) Stock Price, News & Analysis

Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Key Stats

• Today's Range: $51.99 to $51.99
• 50-Day Range: $51.66 to $51.99
• 52-Week Range: $14.95 to $52.00
• Volume: 113 shs
• Average Volume: 1.68 million shs
• Market Capitalization: $3.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CCXI Stock Analysis - Frequently Asked Questions

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.13. The biopharmaceutical company earned $17.74 million during the quarter, compared to analysts' expectations of $14.70 million. ChemoCentryx had a negative trailing twelve-month return on equity of 48.52% and a negative net margin of 357.01%.

What other stocks do shareholders of ChemoCentryx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ChemoCentryx investors own include Energy Transfer (ET), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META), HubSpot (HUBS) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CCXI
• CIK: 1340652
• Web: www.chemocentryx.com
• Phone: (650) 210-2900
• Fax: 650-210-2910
• Employees: 178
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$131.76 million
• Net Margins: -357.01%
• Pretax Margin: -357.01%
• Return on Equity: -48.52%
• Return on Assets: -30.59%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 4.54
• Quick Ratio: 4.47

Sales & Book Value

• Annual Sales: $32.22 million
• Price / Sales: 115.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.09 per share
• Price / Book: 12.71

Miscellaneous

• Outstanding Shares: 71,356,000
• Free Float: 65,433,000
• Market Cap: $3.71 billion
• Optionable: Optionable
• Beta: 1.22